BioSpace News Archive

SpendEdge, a global procurement market intelligence firm, has announced the availability of its Global Clinical Bioanalytical Testing Including Genomics Market Procurement Intelligence Report for preorder.

Digestive symptoms are common in COVID-19, occurring as the chief complaint in nearly half of patients presenting to hospital according to a new descriptive, cross-sectional multicenter study from China by investigators from the Wuhan Medical Treatment Expert Group for COVID-19 published today in The American Journal of Gastroenterology, the official publication of the American College of Gastroenterology.

Crescita Therapeutics Inc. (TSX: CTX OTC) (US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today reported its financial results for the fourth quarter (“Q4-F2019") and fiscal year ended December 31, 2019 (“F2019").

Rhythm Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to setmelanotide for the treatment Alström syndrome. People living with Alström syndrome may experience an insatiable hunger, also known as hyperphagia, and severe

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2019. Key highlights include: Fourth quarter (Q4) 2019 Net Revenues of $5,569,286 decreased by 6% versus Q4 2018 Full year (FY) 2019 Net Revenues of $21,424,324 flat versus FY 2018 Q4 2019 Canadian Pharmaceutical Net Revenues of $5,042,899 flat versus Q4 2018 FY 2019 Canadian Pharmaceutic

MPLT Healthcare, one of the nation’s fastest growing locum tenens healthcare staffing companies, is ready to support healthcare systems in need during the evolving COVID-19 situation.

Pharmascience Inc. is proud to bring to market a new product for the maintenance treatment of asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic alternative to ADVAIR DISKUS™ is now available in Canada in the same inhaler device as *ADVAIR DISKUS™.

Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday, March 24, 2020.

Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline